Backed by Research - Key Probiotic Studies & Insights:

1. VigiBIOM (Vivekanandan et al., 2024) - Vaginal Suppository, RCT

A randomized, double‑blind, placebo‑controlled trial demonstrated that a multi‑Lactobacillus vaginal suppository administered for 28 days significantly lowered vaginal pH and reduced Nugent scores among peri- and premenopausal women with bacterial vaginosis (BV)  .

[Read the full study here.] https://pubmed.ncbi.nlm.nih.gov/38336815/

2. MED-01 (Park et al., 2023) - Oral Probiotic, 12-Week RCT

In a multicenter, double‑blind, placebo‑controlled trial with over 100 reproductive-aged women, daily oral intake of the MED‑01 probiotic reduced Nugent scores and improved vaginal microbiota balance, increasing beneficial Lactobacillus plantarum while suppressing harmful bacteria. Though pH wasn’t the primary outcome, improved microbiota implies likely pH benefits  .

3. Lactin-V (L. crispatus CTV-05) – Post-Antibiotic Probiotic

This investigational live biotherapeutic agent, administered intravaginally after antibiotic treatment for BV, significantly reduced recurrence rates, implying restoration of protective Lactobacillus dominance—and by extension, improved vaginal acidity (lower pH)  .

4. L. rhamnosus TOM 22.8 – Pilot Clinical Assessment

A pilot in‑vivo study administering this vaginally sourced strain (both orally and intravaginally) showed significant reductions in pathogens and sustained maintenance of vaginal eubiosis up to 30 days post-treatment—suggesting a pH-stabilizing effect through microbiome restoration  .

FDA DISCLAIMER:

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.